It has already been shown that targeting ephrin-A5, a molecule which is expressed by reactive astrocytes in the peri-infarct region, improves recovery after stroke in mice (Overman et al., 2012), and that currently used antidepressant drugs act by rescuing astrocytic defects, such as d-serine decrease (Malkesman et al., 2012). The gene discussed is EFNA5; the disease is stroke disorder.